225 related articles for article (PubMed ID: 26417223)
1. Post transplant lymphoproliferative disorder: a case series and review of literature.
Cader RA; Mohd R; Gafor HA; Kong NC
EXCLI J; 2013; 12():144-9. PubMed ID: 26417223
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
3. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
4. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
5. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
6. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
Cockfield SM; Preiksaitis JK; Jewell LD; Parfrey NA
Transplantation; 1993 Jul; 56(1):88-96. PubMed ID: 8333073
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
Rouphael B; Lankireddy S; Lazaryan A; Kukla A; Ibrahim HN; Matas AJ; Issa N
Clin Transplant; 2016 Jan; 30(1):60-5. PubMed ID: 26497471
[TBL] [Abstract][Full Text] [Related]
8. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
9. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
10. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
Srivastava T; Zwick DL; Rothberg PG; Warady BA
Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
[TBL] [Abstract][Full Text] [Related]
11. Posttransplant Lymphoproliferative Disorder in Adults Receiving Kidney Transplantation in British Columbia: A Retrospective Cohort Analysis.
Ready E; Chernushkin K; Partovi N; Hussaini T; Luo C; Johnston O; Shapiro RJ
Can J Kidney Health Dis; 2018; 5():2054358118760831. PubMed ID: 29636980
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
[TBL] [Abstract][Full Text] [Related]
13. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
Liu M; Husain S; Famure O; Li Y; Kim SJ
Prog Transplant; 2019 Jun; 29(2):185-193. PubMed ID: 30845885
[TBL] [Abstract][Full Text] [Related]
14. Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience.
Muchtar E; Kramer MR; Vidal L; Ram R; Gurion R; Rosenblat Y; Bakal I; Shpilberg O
Transplantation; 2013 Oct; 96(7):657-63. PubMed ID: 23823652
[TBL] [Abstract][Full Text] [Related]
15. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients.
Reams BD; McAdams HP; Howell DN; Steele MP; Davis RD; Palmer SM
Chest; 2003 Oct; 124(4):1242-9. PubMed ID: 14555552
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
[TBL] [Abstract][Full Text] [Related]
17. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder.
Purighalla R; Shapiro R; Jordan ML; Scantlebury VP; Gritsch HA; Vivas C; Randhawa PS
Clin Transplant; 1997 Dec; 11(6):574-6. PubMed ID: 9408687
[TBL] [Abstract][Full Text] [Related]
18. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients.
Praghakaran K; Wise B; Chen A; Schwarz K; Colombani P
J Pediatr Surg; 1999 Jan; 34(1):112-5; discussion 115-6. PubMed ID: 10022154
[TBL] [Abstract][Full Text] [Related]
19. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
[TBL] [Abstract][Full Text] [Related]
20. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]